Background {#Sec1}
==========

*Streptococcus pneumoniae* can result in a range of diseases, from invasive pneumococcal diseases (IPDs) (e.g. meningitis and bacteremia) to pneumonia and acute otitis media (AOM) \[[@CR1]\]. Data from the World Health Organization (WHO) suggest that pneumococcal diseases caused around 480,000 deaths among children under 5 years of age in 2008 \[[@CR2]\], making it the leading cause of vaccine-preventable death among children globally \[[@CR3]\]. In addition, pneumonia has been reported as the fourth leading cause of death in 2009 among the Ministry of Health hospitals in Malaysia, accounting for 10.4% of inpatient deaths \[[@CR4]\]. Although AOM is a much milder disease than pneumonia or IPDs, it is very common and is therefore associated with substantial impacts on healthcare costs and quality of life \[[@CR5], [@CR6]\]. Invasive disease, pneumonia and AOM can also be caused by microorganisms other than *S. pneumoniae*, including non-typeable *Haemophilus influenzae* (NTHi) \[[@CR7], [@CR8]\].

Pneumococcal conjugate vaccines (PCVs) were recommended as a priority for inclusion in national childhood immunization programs in all countries by the WHO in 2007 \[[@CR9]\]. Although they are not currently included in the national immunization program in Malaysia, two PCVs are available in the private market of Malaysia: a 13-valent pneumococcal conjugate vaccine (PCV13; *Prevenar 13*) and a pneumococcal polysaccharide and NTHi protein D conjugate vaccine (PHiD-CV; *Synflorix*).

Two prior cost-effectiveness analyses have compared a 3+1 schedule using either PHiD-CV or PCV13 in Malaysia \[[@CR10], [@CR11]\], but the results are inconsistent. Aljunid et al. \[[@CR10]\] predicted that PHiD-CV would be more cost-effective than PCV13, but Wu et al. \[[@CR11]\] predicted the opposite. Unlike Aljunid et al. \[[@CR10]\], Wu et al. \[[@CR11]\] did not account for the protective effects of PHiD-CV in a number of key areas: (1) cross-protection against serotypes 6A and 19A, which has been demonstrated in a number of recent studies \[[@CR12]--[@CR14]\]; (2) indirect (herd) protection against IPD, which has been shown in surveillance data from Finland \[[@CR15]\] and New Zealand \[[@CR16]\]; and (3) protection against NTHi AOM, which has been shown in both the randomized controlled Clinical Otitis Media and Pneumonia Study (COMPAS) study \[[@CR17]\] and the randomized controlled Pneumococcal Otitis Efficacy Trial (POET) study of PHiD-CV's 11-valent precursor \[[@CR18]\]. Wu et al.'s \[[@CR11]\] methodology has recently been critiqued by Varghese et al. \[[@CR19]\]. Excluding the protective effects of PHiD-CV in these key areas is against the current evidence and could have had a significant impact on the cost-effectiveness of PHiD-CV versus PCV13. It is therefore necessary to conduct another cost-effectiveness analysis, taking into account the latest evidence of vaccine effectiveness.

The goal of this economic evaluation was to assess the cost-effectiveness of universal mass pneumococcal vaccination with a PHiD-CV 2+1 vaccination strategy versus no vaccination or a PCV13 2+1 vaccination strategy from the perspective of the Malaysian government. The results from this study can provide scientific evidence for Malaysian healthcare policymakers to support their decision making on the introduction of PCV into the national immunization program.

Methods {#Sec2}
=======

A published Markov cohort model \[[@CR20]\] was adapted to simulate the epidemiological and economic burden of pneumococcal and NTHi-related diseases (IPD, pneumonia and AOM) over a 10-year time horizon in Malaysia. In this study, infants could be vaccinated with PHiD-CV 2+1 or PCV13 2+1 or neither, as these are the vaccinations being considered for inclusion in the Malaysian universal mass vaccination program. The model has a number of mutually exclusive disease-related outcomes, namely pneumococcal meningitis, pneumococcal bacteremia, all-cause pneumonia, AOM and no pneumococcal infection (Fig. [1](#Fig1){ref-type="fig"}). Patients with AOM could be hospitalized (myringotomy), visit their general practitioner (GP) or be non-consulting. Patients with pneumonia could be treated as outpatients or inpatients. Those with meningitis, bacteremia or hospitalized pneumonia were at risk of death. Individuals of the birth cohort moved between the Markov states according to estimated transition probabilities. The reason for choosing 10 years' time horizon in the base case is because we assumed that the duration of vaccine protection to be 10 years for the 2+1 regimen. In addition, it is because the serotypes are changing over time due to the vaccination program \[[@CR21]\].Fig. 1Model structure. *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *PCV13* 13-valent pneumococcal conjugate vaccine, *AOM* acute otitis media, *GP* general practitioner

The analyses were conducted from the perspective of the Malaysian government for a birth cohort of 508,774 in 2012 \[[@CR22]\]. Costs and quality-adjusted life-years (QALYs) were discounted at 3% per annum according to Malaysian guidelines \[[@CR23]\]. All costs are reported in 2014 United States dollars (USD), converted when necessary from Malaysian Ringgits (MYR) using the exchange rate as at 31 Dec 2014 (3.5 MYR = 1 USD) \[[@CR24]\]. The model and all-related data inputs and assumptions were reviewed and validated by a group of local clinical and health economics experts to ensure the validity of the model adaptation in the local setting.

Epidemiological data (Table [1](#Tab1){ref-type="table"}) {#Sec3}
---------------------------------------------------------

Age-specific incidence data for hospitalized pneumococcal meningitis and bacteremia (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and hospitalized all-cause pneumonia (Additional file [1](#MOESM1){ref-type="media"}: Table S2) were sourced from a study that estimated disease burden from the hospital records of six tertiary hospitals across Malaysia during 2006--2007 \[[@CR25]\]. Malaysian case fatality ratios (CFRs) were not available, so we referred to the CFRs from a retrospective population-based National Health Insurance Reimbursement Database study from Taiwan \[[@CR26]\] (Additional file [1](#MOESM1){ref-type="media"}: Tables S1 and S2). This approach was conservative, considering Taiwan has a more advanced healthcare system and better healthcare access than Malaysia. GP consultation rates for all-cause pneumonia (Additional file [1](#MOESM1){ref-type="media"}: Table S2) were also lacking in Malaysia, but hospitalized pneumonia incidence rates were available. Therefore, an estimate was calculated, based on Malaysian hospitalization rates \[[@CR25]\] and the ratio of Taiwanese GP consultation to hospitalization rates \[[@CR26]\], considering similar healthcare access level within a country. Due to a lack of local/regional data on the long-term sequelae of IPD, these were not included.Table 1Country-specific model parameters for MalaysiaParameterValue in children aged \<5 yReferencesRange^a^PSA distributionBirth cohort size (2012)508,774\[[@CR21]\]Not variedNAHospitalized pneumococcal meningitis Incidence (per 100,000)^b^34.7\[[@CR25]\]±50%Triangular CFR (%)^b^12.5--19.2\[[@CR26]\]±20%TriangularHospitalized pneumococcal bacteremia Incidence (per 100,000)^b^46.3\[[@CR25]\]±50%Triangular CFR (%)^b^4.1--4.9\[[@CR26]\]±20%TriangularAll-cause pneumonia GP consultation rate (per 100,000)^c^4600--12,517\[[@CR25], [@CR26]\]±50%Triangular Hospitalization rate (per 100,000)^c^765.8\[[@CR25]\]±20%Triangular CFR (%)^c^0.0--0.4\[[@CR26]\]±20%TriangularAll-cause AOM GP consultation rate (per 100,000)^d^11,745--16,412\[[@CR27]\]±50%Triangular Myringotomy procedures (per 100,000)^d^10.8--27.2\[[@CR26], [@CR27]\]±20%Triangular*AOM* acute otitis media, *CFR* case fatality ratio, *GP* general practitioner, *PSA* probabilistic sensitivity analysis, *NA* not applicable^a^Ranges used in the one-way sensitivity analyses^b^Age-specific values are in Additional file [1](#MOESM1){ref-type="media"}: Table S1^c^Age-specific values are in Additional file [1](#MOESM1){ref-type="media"}: Table S2^d^Age-specific values are in Additional file [1](#MOESM1){ref-type="media"}: Table S3

Age-specific AOM GP consultation rates (Additional file [1](#MOESM1){ref-type="media"}: Table S3) were based on published data from the Philippines \[[@CR27]\] due to the lack of Malaysian data. Myringotomy rates (Additional file [1](#MOESM1){ref-type="media"}: Table S3) were adapted from data from the Philippines \[[@CR27]\] that were based on insurance data from Taiwan \[[@CR26]\] and consultation with local ear, nose and throat experts. In the base case, all cases of AOM were assumed to result in a GP consultation. Complications and long-term sequelae of AOM were very conservatively not taken into account, due to a lack of suitable data.

Vaccine effectiveness data (Table [2](#Tab2){ref-type="table"}) {#Sec4}
---------------------------------------------------------------

Vaccination was assumed to occur at ages 2, 4 and 13 months. In the base case, it was assumed that 100% of infants would be vaccinated, as WHO 2015 immunization coverage estimates for Malaysia for other childhood vaccines were close to 100% \[[@CR28]\]. It was further assumed that all children would receive the defined number of doses at the recommended times, hence the effect of partial vaccination was not considered. Both vaccines were assumed to cost USD 34.25 per dose (hypothetical price). Due to a lack of local data, administration costs were not considered; and vaccine wastage was assumed to be 0%.Table 2Vaccine-specific model parametersParameterPHiD-CVPCV13Range^a^PSA distributionVaccination ages (months)2, 4 and 132, 4 and 13Not variedNAVaccination coverage (%)100 \[[@CR28]\]100 \[[@CR28]\]Not variedNAVaccine cost (USD/dose)34.25 (hypothetical price)34.25 (hypothetical price)Not variedNAVEs/effectivenesses (%) IPD  Vaccine serotypes (excluding ST3)94.7 (based on PCV7 data \[[@CR31]\])94.7 (based on PCV7 data \[[@CR31]\])95% CI^b^Lognormal  ST30 (assumption)26 (based on PCV13 data \[[@CR32]\])Not variedNA  Cross-protection for ST6A76.0 (based on PCV7 data \[[@CR31], [@CR36]\])NA95% CI^c^Lognormal  Cross-protection for ST19A82.2 (based on PHiD-CV surveillance \[[@CR14]\])NA95% CI^c^Lognormal All-cause pneumonia  Hospitalized21.8 (based on PHiD-CV data \[[@CR17]\])21.8 (based on PHiD-CV data \[[@CR17]\])95% CILognormal  GP visit8.7 (based on PHiD-CV data \[[@CR17]\])8.7 (based on PHiD-CV data \[[@CR17]\])95% CILognormal All-cause AOM  Vaccine serotypes (excluding ST3)69.9 (based on PHiD-CV data \[[@CR17]\])69.9 (based on PHiD-CV data \[[@CR17]\])95% CILognormal  Cross-protection for ST6A63.7 (based on PHiD-CV precursor data \[[@CR18]\])NANot varied^c^NA  Cross-protection for ST19A61 (based on PHiD-CV and PCV7 data \[[@CR14], [@CR17], [@CR31]\])^d^NANot varied^c^NA  ST30 (assumption)0 (assumption due to a lack of relevant data)Not variedNA  Non-vaccine serotypes--33 (based on PCV7 data \[[@CR43]\])--33 (based on PCV7 data \[[@CR43]\])95% CILognormal  NTHi21.5 (based on PHiD-CV data \[[@CR17]\])--11 (based on PCV7 data \[[@CR43]\])95% CILognormal  Overall24.1 (based on the above and pathogen split from \[[@CR41], [@CR42]\])14.2 (based on the above and pathogen split from \[[@CR41], [@CR42]\])Not variedNA*AOM* acute otitis media, *CI*, confidence interval, *GP* general practitioner, *IPD* invasive pneumococcal disease, *NA* not applicable, *NTHi* non-typeable *Haemophilus influenzae*, *PCV7* 7-valent pneumococcal conjugate vaccine, *PCV13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *ST* serotype, *USD* United States dollars, *VE* vaccine efficacy, *PSA* probabilistic sensitivity analysis^a^Ranges used in the one-way sensitivity analyses^b^Lowest and highest vaccine-type 95% CIs from \[[@CR31]\] used for all serotypes^c^Not applicable for PCV13^d^Estimated based on PHiD-CV VE against 19A IPD \[[@CR14]\], PCV7 VE against vaccine serotype IPD \[[@CR31]\], and PHiD-CV VE against vaccine serotype AOM \[[@CR17]\]

Vaccine effectiveness was assumed to have a ramp-up increase from age 2--13 months (50% after dose 1; 90% after dose 2), have full effectiveness from age 13 months to 3 years, and have waning effectiveness (exponential decline) to age 10 years \[[@CR20]\].

Against IPD, PHiD-CV has been estimated to have vaccine efficacies (VEs) of 92% for the 2+1 schedule and 100% for the 3+1 schedule in the randomized, controlled Finnish Invasive Pneumococcal disease (FinIP) trial \[[@CR29]\]. However, PCV13 has no published randomized controlled trial data against IPD. Therefore, vaccine effectiveness against IPD (pneumococcal meningitis and bacteremia) for both vaccines was estimated based on serotype distribution in Malaysia and serotype-specific efficacies. Serotype distribution was based on data from 217 invasive strains isolated in Malaysia in 2008--2009 \[[@CR30]\] (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Based on the average VE of PCV7 against its seven serotypes \[[@CR31]\], a VE of 94.7% was used for the 10 serotypes included in both vaccines (1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F, 23F) and for 6A and 19A for PCV13. However, serotype 3 in PCV13 has generally been shown to be less effective \[[@CR32]--[@CR35]\], so a VE of 26% was assumed \[[@CR32]\]. Post-marketing surveillance studies of PHiD-CV have demonstrated cross-protection of PHiD-CV against 19A IPD with vaccine effectivenesses of 62% (95% confidence interval \[CI\] 20--85%) in Finland \[[@CR13]\], 71% (95% CI 24--89%) in Canada \[[@CR12]\] and 82.2% (95% CI 10.7--96.4%) in Brazil \[[@CR14]\]. Based on local expert opinion, 82.2% from Brazil \[[@CR14]\] was used, due to the potential similarity of economic status, healthcare systems and seasonality. Cross-protection of PHiD-CV against serotype 6A was based on cross-protection of PCV7 against serotype 6A (76.0% \[[@CR31]\]), as PHiD-CV has been demonstrated to be immunogenically non-inferior to PCV7 \[[@CR36]\].

Vaccine effectiveness against all-cause pneumonia is lower than against IPD as it can be caused by a number of pathogens. VE against all-cause pneumonia has been reported in various trials, with PCV7 (18% \[95% CI 5--29%\] \[[@CR37]\]), PCV9 (20% \[95% CI 2--35%\] \[[@CR38]\] and 35% \[95% CI 26--43%\] \[[@CR39]\]), PHiD-CV (22% \[95% CI 8--34%\] \[[@CR17]\]) and PCV11 (16% \[95% CI --7 to 34%\] \[[@CR40]\]) (all intention-to-treat analyses), with no relationship between valency and VE. As there are no published randomized controlled studies for PCV13 against all-cause pneumonia, we used the value of 21.8% for consolidated pneumonia from COMPAS (PHiD-CV) \[[@CR17]\] as the VE against pneumonia hospitalizations for both vaccines. VE against all-cause suspected pneumonia (8.7%) was taken from the same study \[[@CR17]\] and was used for pneumonia associated with a GP visit.

Overall vaccine effectiveness against AOM was estimated based on causative pathogens (*S. pneumoniae*, *H. influenzae* or other) and VE against vaccine and non-vaccine *S. pneumoniae* serotypes and NTHi. Based on a review paper by Leibovitz et al. \[[@CR41]\] of 17 AOM etiology studies across the world, we assumed that 35.9% of AOM cases were attributable to *S. pneumoniae* and 32.3% to NTHi. Data from a multinational AOM study were used for the percentages of AOM cases caused by each serotype \[[@CR42]\]. VE against vaccine-type *S. pneumoniae* (excluding serotype 3) for both vaccines was taken to be 69.9% based on COMPAS \[[@CR17]\]. For PHiD-CV, vaccine efficacies of 63.7% \[[@CR18]\] and 61% \[[@CR14], [@CR17], [@CR31]\] for serotypes 6A and 19A, respectively, were used. For both vaccines, a negative VE of −33% was used against other non-vaccine serotypes based on PCV7 data \[[@CR43]\]. This study also gave a VE for PCV7 against *H. influenzae* AOM of −11% \[[@CR43]\], which was used for PCV13. Two studies have demonstrated efficacy of PHiD-CV \[[@CR17]\] (or its 11-valent precursor \[[@CR18]\]) against NTHi AOM. The lower value of 21.5% (95% CI−43.4 to 57.0%) from COMPAS \[[@CR17]\] was used. Although the 95% CI spans zero, it should be noted that the COMPAS trial \[[@CR17]\] was not powered to provide conclusive evidence of protection against NTHi AOM. However, the positive effect of PHiD-CV against NTHi AOM is consistent with the significant efficacy observed with the 11-valent predecessor protein D conjugate formulation used in the POET study (35.3% \[95% CI 1.8--57.4%\]) \[[@CR18]\]. The overall estimated vaccine effectivenesses against AOM were 24.1% for PHiD-CV and 14.2% for PCV-13.

No vaccine effectiveness for PHiD-CV against NTHi invasive disease or pneumonia was assumed due to a lack of evidence. Indirect effects (herd protection and serotype replacement) were also not taken into account in the base case.

Health outcomes (Table [3](#Tab3){ref-type="table"}) {#Sec5}
----------------------------------------------------

Due to a lack of published pneumococcal disease-related disutility weights in Malaysia, short-term disutility data from the US \[[@CR44]\] and Canada \[[@CR45]\] were applied to age-specific healthy utilities \[[@CR46]\].Table 3Short-term disutility weights of pneumococcal diseasesDisutility weightReference/assumptionsRange^a^%PSA distributionMeningitis (inpatient)0.023\[[@CR44]\] value for meningitis with recovery±50Beta (α = 7.70, β = 324.15)Bacteremia (inpatient)0.008\[[@CR44]\] value for hospitalization±50Beta (α = 6.46, β = 811.13)Pneumonia (inpatient)0.008Assumed to be the same as for inpatient bacteremia±50Beta (α = 6.62, β = 821.25)Pneumonia (outpatient)0.006\[[@CR44]\] value for local infection±50Beta (α = 3.73, β = 618.18)AOM (outpatient)0.005\[[@CR45]\]±50TriangularAOM (hospitalized myringotomy)0.005Assumed to be the same as for AOM (outpatient)±50Triangular*AOM* acute otitis media, *PSA* probabilistic sensitivity analysis^a^Ranges used in the one-way sensitivity analyses

Treatment costs (Table [4](#Tab4){ref-type="table"}) {#Sec6}
----------------------------------------------------

Only direct medical costs were included. Direct medical costs for acute episodes were based on local published data from 2010 \[[@CR10]\]. Costs were inflated using the consumer price index for heath for Malaysia \[[@CR47]\] to 2014 values and then converted into USD \[[@CR24]\].Table 4Costs for acute episodes of pneumococcal diseases \[[@CR10]\]Weighted average cost (USD 2014)^a^Range^b^ %PSA distributionMeningitis---hospitalized1717±20TriangularBacteremia---hospitalized838±20TriangularPneumonia---ospitalized989±20TriangularPneumonia---outpatient164±20TriangularAOM---hospitalized (myringotomy)583±20TriangularAOM---GP consultation191±20Triangular*AOM* acute otitis media, *GP* general practitioner, *MYR* Malaysian Ringgits, *USD* United States dollars, *PSA* probabilistic sensitivity analysis^a^2010 data in MYR from Aljunid et al. \[[@CR10]\] (calculated as Cost all divided by Total cases per year) were inflated to 2014 values (consumer price index for heath for Malaysia of 111.4 \[[@CR47]\]) and then converted to USD (3.5 MYR = 1 USD \[[@CR24]\])^b^Ranges used in the one-way sensitivity analyses

Cost-effectiveness analysis {#Sec7}
---------------------------

The model estimated cases, costs and QALYs specific to each health state over 10 years from birth for PHiD-CV 2+1, PCV13 2+1 or neither. Incremental cost-effectiveness ratios (ICERs) were computed for PHiD-CV 2+1 versus no vaccination and PHiD-CV 2+1 versus PCV13 2+1. Due to the lack of locally published threshold, the WHO threshold was used to categorize the cost-effectiveness results of this analysis \[[@CR48]\]: a strategy was considered either as dominant (lower cost and more QALYs), highly cost-effective (ICER less than the gross domestic product \[GDP\] per capita of Malaysia \[10,333 USD in 2014 \[[@CR24], [@CR49]\]\]), cost-effective (ICER \< 3 × GDP per capita \[30,999 USD\]) or not cost-effective (ICER ≥ 3 × GDP per capita).

Sensitivity analyses {#Sec8}
--------------------

For comparisons of PHiD-CV 2+1 versus no vaccination or PCV13 2+1, extensive one-way sensitivity analyses were performed to evaluate the robustness of the results. These were mainly performed using values based on the upper and lower limits of 95% CIs for vaccine effectiveness and ±20 or ±50% of base-case values for most other parameters (see Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} for further details).

Probabilistic sensitivity analyses (PSAs) were performed for PHiD-CV 2+1 versus no vaccination or PCV13 2+1, each using 1000 simulations.

Scenario analyses {#Sec9}
-----------------

A set of alternative scenario analyses on parameters of particular interest were performed for comparisons of PHiD-CV 2+1 versus no vaccination or PCV13 2+1: (1) discount rates of 0 and 5, as per Malaysian guidelines \[[@CR23]\]; (2) a lower proportion of AOM cases due to NTHi (20% rather than 32.3%); (3) a different adjustment factor for estimating total AOM cases (i.e. consulting plus non-consulting cases) (0.7 and 1.3 rather than 1.0); (4) a time horizon of 100 rather than 10 years; (5) inclusion of indirect effects (herd protection and serotype replacement) for all age groups and both vaccines (only applied to IPD \[[@CR50]\]); it was assumed that this would reach a steady state of 30% (i.e. 30% reduction in disease incidence).

Results {#Sec10}
=======

Cost-effectiveness analysis {#Sec11}
---------------------------

### PHiD-CV 2+1 versus no vaccination {#Sec12}

It was projected that vaccination with a PHiD-CV 2+1 program would prevent 1109 cases of IPD, 24,679 cases of all-cause pneumonia, 72,940 cases of AOM and 103 IPD/pneumonia deaths compared with no vaccination strategy for the birth cohort of 508,774 in Malaysia over 10 years (Table [5](#Tab5){ref-type="table"}).Table 5Estimated disease burden impacts of no vaccination, PCV13 2+1 and PHiD-CV 2+1 vaccination programsNo vaccinationPCV13PHiD-CVPHiD-CV versus no vaccinationPHiD-CV versus PCV13IPD cases (acute episodes)244412951335--1109+40 Meningitis1021533550--471+17 Bacteremia1423762785--638+23All-cause pneumonia cases (acute episodes)534,819510,143510,140--24,679--3AOM cases (acute episodes)565,764522,825492,824--72,940--30,001Pneumococcal deaths239132136--103+4 IPD209107111--98+4 Pneumonia302525--50*AOM* acute otitis media, *IPD* invasive pneumococcal disease, *PCV13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccineIn Malaysia over 10 years for a birth cohort of 508,774

Undiscounted vaccination costs were estimated to be USD 52.1 million, but these would be partially offset by a reduction in direct medical costs of USD 22.4 million, for a total direct medical cost of USD 29.7 million (Table [6](#Tab6){ref-type="table"}). Discounted total cost and QALY increases were predicted to be USD 30.9 million and 1084 QALYs, respectively, demonstrating a cost-effective ICER of USD 28,497/QALY.Table 6Estimated economic impacts of no vaccination, PCV13 2+1 and PHiD-CV 2+1 vaccination programsNo vaccinationPCV13PHiD-CVPHiD-CV versus no vaccinationPHiD-CV versus PCV13Undiscounted costs (USD) Vaccination costs052,119,71152,119,681+52,119,681--30 Acute episode costs  IPD2945,3071,553,2121,602,129--1,343,178+48,917   Meningitis1,753,066914,936944,383--808,683+29,447   Bacteremia1,192,241638,276657,746--534,495+19,470  All-cause pneumonia106,306,14899,249,56399,249,006--7,057,142--557  AOM108,394,044100,136,09394,366,242--14,027,802--5,769,851 Total direct costs217,645,499253,058,579247,337,058+29,691,559--5,721,521 QALYs4,590,1444,591,2674,591,392+1,248+125 ICER23,792PHiD-CV dominantDiscounted costs (USD)^a^ Total direct costs190,226,159226,321,520221,112,241+30,886,082--5,209,279 QALYs3,979,3313,980,2993,980,415+1084+116 ICER------28,497 (cost-effective)PHiD-CV dominantCosts are in 2014 USD*AOM* acute otitis media, *ICER* incremental cost-effectiveness ratio, *IPD* invasive pneumococcal disease, *PCV13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *QALY* quality-adjusted life-year, *USD* United States dollarsIn Malaysia over 10 years for a birth cohort of 508,774^a^Discounted at 3% per annum \[[@CR23]\]

### PHiD-CV 2+1 versus PCV13 2+1 {#Sec13}

It was projected that vaccination with a PHiD-CV 2+1 program would result in 40 more IPD cases than vaccination with a PCV13 2+1 program, but 30,001 fewer cases of AOM (Table [5](#Tab5){ref-type="table"}). Similarly, undiscounted direct medical costs with PHiD-CV 2+1 were predicted to be somewhat higher for IPD, but substantially lower for AOM, resulting in an overall cost saving of USD 5.7 million (Table [6](#Tab6){ref-type="table"}). Discounted total cost savings and QALYs gained were predicted to be 5.2 million and 116, respectively, meaning that PHiD-CV 2+1 was predicted to be dominant over PCV13 2+1 (lower cost and more QALYs gained).

Sensitivity analyses {#Sec14}
--------------------

### PHiD-CV 2+1 versus no vaccination {#Sec15}

According to one-way sensitivity analyses, the most influential factors on the cost-effectiveness of PHiD-CV 2+1 versus no vaccination were the efficacy of PHiD-CV against NTHi AOM, the AOM GP consultation rate, and the incidence of hospitalized pneumococcal meningitis (Fig. [2](#Fig2){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}: Table S4). In the PSA, the probability of PHiD-CV being cost-effective compared with no vaccination was 31.6% at the cost-effectiveness threshold for Malaysia (Fig. [3](#Fig3){ref-type="fig"}a).Fig. 2Top five most influential factors identified in one-way sensitivity analysis for the cost-effectiveness of PHiD-CV 2+1 versus no vaccination. *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *AOM* acute otitis media, *NTHi* non-typeable *Haemophilus influenzae, GP* general practitioner, *USD* United States dollars Fig. 3PSA results for PHiD-CV 2+1 versus **a** no vaccination and **b** PCV13 2+1 vaccination programs. The "cost-effective" threshold was taken to be 3 × GDP per capita. *GDP* gross domestic product, *PCV13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *PSA* probabilistic sensitivity analysis, *QALY* quality-adjusted life-year, *USD* United States dollars

### PHiD-CV 2+1 versus PCV13 2+1 {#Sec16}

One-way sensitivity analyses showed that the most influential factors were the disutility weight for AOM (outpatient) and PHiD-CV cross-protection for serotype 19A IPD (Fig. [4](#Fig4){ref-type="fig"}); but none of the varied model inputs impacted on the dominant conclusion of PHiD-CV 2+1 over PCV13 2+1 (Additional file [1](#MOESM1){ref-type="media"}: Table S4). The PSA showed PHiD-CV 2+1 to be dominant over PCV13 2+1 in 91.6% of the simulations (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 4Top five most influential factors identified in one-way sensitivity analysis for the cost-effectiveness of PHiD-CV 2+1 versus PCV13 2+1. *AOM* acute otitis media, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *ST19A* serotype 19A, *IPD* invasive pneumococcal disease, *GP* general practitioner, *PCV13* 13-valent pneumococcal conjugate vaccine, *ST6B* serotype 6B, *USD* United States dollars

Scenario analyses {#Sec17}
-----------------

Most of the scenario analyses predicted that PHiD-CV 2+1 would be cost-effective versus no vaccination; running the model over 100 years resulted in a prediction that PHiD-CV 2+1 would be highly cost-effective (Table [7](#Tab7){ref-type="table"}). Scenario analyses predicted PHiD-CV 2+1 to be dominant over PCV13 2+1 for all scenarios tested.Table 7Scenario analyses of PHiD-CV 2+1 versus no vaccination or PCV13 2+1 vaccination programs in MalaysiaParameterBase caseScenario analysisPHiD-CV versus no vaccination (ICER)PHiD-CV versus PCV13 (cost saving \[USD million\]/QALYs gained)Base case----28,497^a^5.2/116Discount rate3%0%23,792^a^5.7/125Discount rate3%5%31,7934.9/110AOM cases due to NTHi32.3%20.0%30,843^a^3.1/60Adjustment factor for total AOM cases1.00.731,3715.2/75Adjustment factor for total AOM cases1.01.326,105^a^5.2/157Time horizon10 years100 years10,317^b^5.2/50Indirect effectsExcludedIncluded21,032^a^5.2/116*AOM* acute otitis media, *ICER* incremental cost-effectiveness ratio, *NTHi* non-typeable *H. influenzae*, *PCV13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* pneumococcal polysaccharide and NTHi protein D conjugate vaccine, *QALY* quality-adjusted life-year, *USD* United States dollars^a^Cost-effective (\<USD 30,999)^b^Highly cost-effective (\<USD 10,333)

Discussion {#Sec18}
==========

In this cost-effectiveness analysis, the adoption of pediatric mass vaccination with a PHiD-CV 2+1 program was predicted to prevent 1109 cases of IPD, 24,679 cases of pneumonia, 72,940 cases of AOM, and 103 IPD/pneumonia-related deaths over 10 years compared with no vaccination program in Malaysia. PHiD-CV 2+1 was predicted to result in 1084 QALYs gained at a cost of USD 30.9 million (discounted), resulting in a cost-effective ICER of USD 28,497/QALY. Our results are in line with various other health economic studies that have predicted that the introduction of routine infant vaccination with PHiD-CV would be cost-effective, including those in Georgia \[[@CR51]\], Latin America \[[@CR52]--[@CR55]\] and Kenya \[[@CR56]\].

Compared with a PCV13 2+1 program, a PHiD-CV 2+1 program was predicted to result in 40 more IPD cases, but 30,001 fewer cases of AOM. This was expected to result in more QALYs gained at a lower overall cost, i.e. PHiD-CV 2+1 was predicted to be dominant over PCV13 2+1. This dominance is in line with various other cost-effectiveness analyses, from Malaysia \[[@CR10]\], Japan \[[@CR57]\], the Philippines \[[@CR27]\], Turkey \[[@CR58]\], Europe \[[@CR20], [@CR59]--[@CR61]\], Canada \[[@CR20]\] and Peru \[[@CR53]\]. However, some studies have predicted the reverse: that PCV13 would be dominant over PHiD-CV (Malaysia and Hong Kong \[[@CR11]\], Colombia \[[@CR62]\], Europe \[[@CR63]\] and Canada \[[@CR64]\]) or more cost-effective than PHiD-CV (Peru \[[@CR65]\]). These differences in predicted outcomes are largely due to the assumptions used. As noted in a recently published critical assessment of economic evaluations involving PHiD-CV and PCV13, "the pivotal assumptions and results of these analyses also depended on which manufacturer sponsored the study" \[[@CR66]\].

We will focus our discussion on the key differences in assumptions of a prior Malaysian study by Wu et al. \[[@CR11]\] (PCV13 dominance) compared with those used in the current study (PHiD-CV dominance): (1) inclusion of herd effects for PCV13 but not PHiD-CV; (2) no cross-protection for PHiD-CV against serotypes 6A and 19A; (3) higher effectiveness of PCV13 against all-cause pneumonia; and 4) no impact of PHiD-CV on NTHi AOM. In addition, recent evidences has shown lower VE for PCV13 against serotype 3 IPD \[[@CR32]--[@CR35]\], which was not reflected in the previous study by Wu et al. \[[@CR11]\].

In the current study, we conservatively chose not to include herd effect for PHiD-CV or PCV13 in the base case, as this would be counteracted by serotype replacement, resulting in an inconclusive overall effect. In one of the scenario analyses, we included an overall beneficial indirect effect. The same net value was used for PHiD-CV and PCV13, as expert advice was that both herd effect and serotype replacement would likely be slightly higher for PCV13, giving a similar net effect. However, it should be noted that inclusion of indirect effects for PCV13, but not for PHiD-CV is considered as unrealistic, given that a population-based observational study of PHiD-CV in Finland \[[@CR13]\] reported a 48% (95% CI 18--69%) reduction in IPD among unvaccinated children aged 2--5 years. Additionally, surveillance data have demonstrated herd effects of PHiD-CV following the introduction of childhood vaccination programs in Finland \[[@CR15]\] and New Zealand \[[@CR16]\].

In the current study, cross-protection of PHiD-CV against non-vaccine serotypes 6A and 19A was accounted for, while no cross-protection was assumed for PHiD-CV against non-vaccine serotypes in the prior Malaysian study \[[@CR11]\]. For serotype 19A, this was based on a number of robustly designed studies \[[@CR12]--[@CR14]\]. The available evidences have recently prompted the European Medicines Agency to include protection against 19A IPD in PHiD-CV's label \[[@CR67]\]. A similar label update was approved in Canada \[[@CR68]\] and is underway in many countries. Although the evidence for cross-protection against serotype 6A is less conclusive, the data generally indicate that cross-protection is likely \[[@CR13], [@CR14]\] and would be similar to that seen with PCV7 \[[@CR43], [@CR69]\].

We assumed that PHiD-CV and PCV13 would have equal effectivenesses against all-cause pneumonia, based on a number of studies of different valent vaccines with overlapping 95% CIs \[[@CR17], [@CR37]--[@CR40]\]. It is inappropriate to assume that vaccine effectiveness against all-cause pneumonia would be related to the number of serotypes in the vaccine. This type of serotype-based approach has recently been criticized by Hausdorff et al. \[[@CR70]\], because currently available pneumonia efficacy data provide no indication of a trend for greater protection with higher valence vaccines.

Lastly, cautions should be made when assuming that PHiD-CV had no effect against NTHi AOM, merely based on a few studies in which PHiD-CV was shown to have no effect on nasopharyngeal colonization \[[@CR71]--[@CR73]\] without looking into other available evidences. Several randomized controlled studies have reported a beneficial effect of PHiD-CV (or its 11-valent precursor) against NTHi AOM \[[@CR17], [@CR18]\]; and Prymula et al. \[[@CR18]\] also reported a 41.4% (95% CI −4.9 to 67.3%) VE against nasopharyngeal carriage. Furthermore, Australian studies have reported less NTHi-infected middle-ear discharge among those with AOM with perforation or chronic suppurative otitis media vaccinated with PHiD-CV versus PCV7 (35% vs.53% of ear discharge swabs; p = 0.03) \[[@CR74]\] and with PHiD-CV versus PCV13 (36% vs 64% of swabs; p = 0.05) \[[@CR75]\]. Also, a randomized controlled PCV7 trial \[[@CR43]\] showed that the number of *H. influenzae* AOM cases was increased in the PCV7 group. In the absence of PCV13-specific data, we assumed that PCV13 would also increase NTHi AOM cases (vaccine efficacy −11%).

Guidelines from the International Society for Pharmacoeconomics and Outcomes Research recommend that all evidence---not selected sources---should be incorporated into health economic studies \[[@CR76]\]. By incorporating the wider body of evidence available around these critical parameters and employing robust sensitivity analyses, we believe that we have addressed the associated uncertainties and attempted to present a more balanced result. As mentioned previously, outcomes of health economic studies of PHiD-CV and PCV13 can be biased, depending on the sponsor \[[@CR66]\]. Therefore, decision makers should be encouraged to rigorously evaluate the underlying assumptions in all cost-effectiveness analyses.

Strengths and limitations {#Sec19}
-------------------------

As discussed above, the results of cost-effectiveness analyses very much depend on the input parameters used. In the absence of a head-to-head PHiD-CV versus PCV13 trial, we based effectiveness estimates on serotype distribution and data from various clinical trials. Additionally, there are also no randomized controlled PCV13 efficacy studies, hence we extrapolated effectiveness (based on serotype distribution and PCV7 vaccine serotype VE) or assumed values to be the same as for PHiD-CV. We note that VE data were taken from studies of 3+1 schedules, whereas the current model used a 2+1 schedule. This approach was based on the results of a PHiD-CV trial that reported similar vaccine effectivenesses of 100% (95% CI 83--100%) for a 3+1 schedule and 92% (95% CI 58--100%) for a 2+1 schedule against vaccine-type IPD \[[@CR29]\]. Therefore, it is likely that we slightly overestimated the effectiveness of a PHiD-CV 2+1 schedule. However, the same approach was taken for PCV13, so this would have had little effect on the between-vaccine comparison.

Although Malaysian data were used where possible, this was not always feasible, so some data from other countries (Asian when available) had to be used; but this was approved by local clinical experts. However, for some inputs, it was not possible to find any suitable sources, so administration costs, other vaccine program-related costs (e.g. capital costs, logistics costs) and vaccine wastage were all assumed to be zero. Although this could overestimate the cost-effectiveness of PHiD-CV versus no vaccination, there would be no impact on the between-vaccine comparison. We also assumed that all children would receive the recommended number of doses, but in reality, it is likely that some children would not receive the full schedule. This would have resulted in a slightly lower efficacy but also slightly lower costs.

Lastly, the cost-effectiveness thresholds that we used were those recommended by the WHO at the time of the study \[[@CR48]\]. These have recently been criticized \[[@CR77]\], but in the absence of new recommendations, we have used the old thresholds.

Conclusions {#Sec20}
===========

In this cost-effectiveness analysis, a PHiD-CV 2+1 universal vaccination program could potentially prevent a substantial number of cases of pneumococcal diseases compared with no vaccination, and was projected to be a cost-effective strategy in Malaysia. A PHiD-CV 2+1 vaccination program was also predicted to be dominant (more QALYs gained at a reduced overall cost) over a PCV13 2+1 strategy.
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**Additional file 1.** Additional input data and one-way sensitivity analysis results.

AOM

:   acute otitis media

CFR

:   case fatality ratio

CI

:   confidence interval

COMPAS

:   Clinical Otitis Media and Pneumonia Study

FinIP

:   Finnish Invasive Pneumococcal disease

GDP

:   gross domestic product

GP

:   general practitioner

ICER

:   incremental cost-effectiveness ratio

IPD

:   invasive pneumococcal disease

MYR

:   Malaysia Ringgits

NTHi

:   non-typeable *Haemophilus influenzae*

PCV

:   pneumococcal conjugate vaccine

PCV13

:   13-valent pneumococcal conjugate vaccine

PHiD-CV

:   pneumococcal polysaccharide and NTHi protein D conjugate vaccine

POET

:   Pneumococcal Otitis Efficacy Trial

PSA

:   probabilistic sensitivity analysis

QALY

:   quality-adjusted life-year

USD

:   United States dollars

VE

:   vaccine efficacy

WHO

:   World Health Organization
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